메뉴 건너뛰기




Volumn 120, Issue 23, 2014, Pages 3651-3659

Patient preferences in advanced or recurrent ovarian cancer

Author keywords

Chemotherapy; Ovarian cancer; Patient preferences; Progression free survival; Side effects

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

EID: 84913616666     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28940     Document Type: Article
Times cited : (68)

References (23)
  • 1
    • 30044438368 scopus 로고    scopus 로고
    • Intraperitoneal cisplatin and paclitaxel in ovarian cancer
    • Armstrong DK, Bundy B, Wenzel L., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006; 354:34-43.
    • (2006) N Engl J Med. , vol.354 , pp. 34-43
    • Armstrong, D.K.1    Bundy, B.2    Wenzel, L.3
  • 2
    • 84882998935 scopus 로고    scopus 로고
    • Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): A randomised, controlled, open-label trial
    • Katsumata N, Yasuda M, Isonishi S., et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 2013; 14:1020-1026.
    • (2013) Lancet Oncol. , vol.14 , pp. 1020-1026
    • Katsumata, N.1    Yasuda, M.2    Isonishi, S.3
  • 3
    • 84855425106 scopus 로고    scopus 로고
    • Incorporation of beva-cizumab in the primary treatment of ovarian cancer
    • Burger RA, Brady MF, Bookman M.A., et al. Incorporation of beva-cizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011; 365:2473-2483.
    • (2011) N Engl J Med. , vol.365 , pp. 2473-2483
    • Burger, R.A.1    Brady, M.F.2    Bookman, M.A.3
  • 4
    • 84859523588 scopus 로고    scopus 로고
    • Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
    • Ledermann J, Harter P, Gourley C., et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012; 366:1382-1392.
    • (2012) N Engl J Med. , vol.366 , pp. 1382-1392
    • Ledermann, J.1    Harter, P.2    Gourley, C.3
  • 5
    • 57649115547 scopus 로고    scopus 로고
    • Cancer patient preferences for quality and length of life
    • Meropol NJ, Egleston BL, Buzaglo J.S., et al. Cancer patient preferences for quality and length of life. Cancer. 2008; 113:3459-3466.
    • (2008) Cancer , vol.113 , pp. 3459-3466
    • Meropol, N.J.1    Egleston, B.L.2    Buzaglo, J.S.3
  • 7
    • 0030248005 scopus 로고    scopus 로고
    • Patients' preferences for therapy in advanced epithelial ovarian cancer: Development, testing, and application of a bedside decision instrument
    • Elit LM, Levine MN, Gafni A, et al. Patients' preferences for therapy in advanced epithelial ovarian cancer: development, testing, and application of a bedside decision instrument. Gynecol Oncol. 1996; 62:329-335.
    • (1996) Gynecol Oncol. , vol.62 , pp. 329-335
    • Elit, L.M.1    Levine, M.N.2    Gafni, A.3
  • 8
    • 84892795291 scopus 로고    scopus 로고
    • Ovarian cancer clinical trial endpoints: Society of gynecologic oncology white paper
    • Herzog TJ, Armstrong DK, Brady M.F., et al. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. Gynecol Oncol. 2014; 132:8-17.
    • (2014) Gynecol Oncol. , vol.132 , pp. 8-17
    • Herzog, T.J.1    Armstrong, D.K.2    Brady, M.F.3
  • 9
    • 79959944619 scopus 로고    scopus 로고
    • Conjoint analysis applications in health - A checklist: A report of the ISPOR good research practices for conjoint analysis task force
    • Bridges JF, Hauber AB, Marshall D, et al. Conjoint analysis applications in health-a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011; 14: 403-413.
    • (2011) Value Health , vol.14 , pp. 403-413
    • Bridges, J.F.1    Hauber, A.B.2    Marshall, D.3
  • 10
    • 0035868845 scopus 로고    scopus 로고
    • Reliability and validity of the functional assessment of cancer therapy-ovarian
    • Basen-Engquist K, Bodurka-Bevers D, Fitzgerald M.A., et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Ovarian. J Clin Oncol. 2001; 19:1809-1817.
    • (2001) J Clin Oncol. , vol.19 , pp. 1809-1817
    • Basen-Engquist, K.1    Bodurka-Bevers, D.2    Fitzgerald, M.A.3
  • 11
    • 0034306866 scopus 로고    scopus 로고
    • Assessing symptom distress in cancer patients: The MD anderson symptom inventory
    • Cleeland CS, Mendoza TR, Wang X.S., et al. Assessing symptom distress in cancer patients: the MD Anderson Symptom Inventory. Cancer. 2000; 89:1634-1646.
    • (2000) Cancer , vol.89 , pp. 1634-1646
    • Cleeland, C.S.1    Mendoza, T.R.2    Wang, X.S.3
  • 12
    • 0034600459 scopus 로고    scopus 로고
    • Using conjoint analysis to elicit preferences for health care
    • Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. BMJ. 2000; 320:1530-1533.
    • (2000) BMJ , vol.320 , pp. 1530-1533
    • Ryan, M.1    Farrar, S.2
  • 13
    • 84861719741 scopus 로고    scopus 로고
    • Patients' preferences for treatment outcomes for advanced nonsmall cell lung cancer: A conjoint analysis
    • Bridges JF, Mohamed AF, Finnern H.W., Woehl A., Hauber AB. Patients' preferences for treatment outcomes for advanced nonsmall cell lung cancer: a conjoint analysis. Lung Cancer. 2012; 77:224-231.
    • (2012) Lung Cancer , vol.77 , pp. 224-231
    • Bridges, J.F.1    Mohamed, A.F.2    Finnern, H.W.3    Woehl, A.4    Hauber, A.B.5
  • 14
    • 84855545457 scopus 로고    scopus 로고
    • Discrete choice experiments in health economics: A review of the literature
    • de Bekker-Grob EW, Ryan M, Gerard K. Discrete choice experiments in health economics: a review of the literature. Health Econ. 2012; 21:145-172.
    • (2012) Health Econ. , vol.21 , pp. 145-172
    • De Bekker-Grob, E.W.1    Ryan, M.2    Gerard, K.3
  • 15
    • 84872731697 scopus 로고    scopus 로고
    • Constructing experimental designs for discrete-choice experiments: Report of the ISPOR conjoint analysis experimental design good research practices task force
    • Reed Johnson F, Lancsar E, Marshall D., et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health. 2013; 16:3-13.
    • (2013) Value Health , vol.16 , pp. 3-13
    • Reed Johnson, F.1    Lancsar, E.2    Marshall, D.3
  • 16
    • 80051913984 scopus 로고    scopus 로고
    • 2010 gynecologic cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: Report from the fourth ovarian cancer consensus conference
    • Stuart GC, Kitchener H, Bacon M., et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 2011; 21:750-755.
    • (2011) Int J Gynecol Cancer , vol.21 , pp. 750-755
    • Stuart, G.C.1    Kitchener, H.2    Bacon, M.3
  • 17
    • 0141688377 scopus 로고    scopus 로고
    • Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A gynecologic oncology group study
    • Ozols RF, Bundy BN, Greer B.E., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003; 21:3194-3200.
    • (2003) J Clin Oncol. , vol.21 , pp. 3194-3200
    • Ozols, R.F.1    Bundy, B.N.2    Greer, B.E.3
  • 18
    • 58849091878 scopus 로고    scopus 로고
    • Using conjoint analysis to estimate healthy-year equivalents for acute conditions: An application to vasomotor symptoms
    • Johnson FR, Hauber AB, Ozdemir S. Using conjoint analysis to estimate healthy-year equivalents for acute conditions: an application to vasomotor symptoms. Value Health. 2009; 12:146-152.
    • (2009) Value Health , vol.12 , pp. 146-152
    • Johnson, F.R.1    Hauber, A.B.2    Ozdemir, S.3
  • 19
    • 84873744492 scopus 로고    scopus 로고
    • Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: A gynecologic oncology group study
    • Monk BJ, Huang HQ, Burger R.A., et al. Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2013; 128:573-578.
    • (2013) Gynecol Oncol. , vol.128 , pp. 573-578
    • Monk, B.J.1    Huang, H.Q.2    Burger, R.A.3
  • 21
    • 1542289007 scopus 로고    scopus 로고
    • A quality-adjusted survival (Q-TWiST) model for evaluating treatments for advanced stage cancer
    • Cole BF, Gelber RD, Gelber S, Mukhopadhyay P. A quality-adjusted survival (Q-TWiST) model for evaluating treatments for advanced stage cancer. J Biopharm Stat. 2004; 14:111-124.
    • (2004) J Biopharm Stat. , vol.14 , pp. 111-124
    • Cole, B.F.1    Gelber, R.D.2    Gelber, S.3    Mukhopadhyay, P.4
  • 22
    • 8244254377 scopus 로고    scopus 로고
    • Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
    • Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15:2403-2413.
    • (1997) J Clin Oncol. , vol.15 , pp. 2403-2413
    • Burris, H.A.1    Moore, M.J.2    Andersen, J.3
  • 23
    • 68749107026 scopus 로고    scopus 로고
    • Clinical benefit in oncology trials: Is this a patient-centred or tumour-centred end-point?
    • Ohorodnyk P, Eisenhauer EA, Booth CM. Clinical benefit in oncology trials: is this a patient-centred or tumour-centred end-point? Eur J Cancer. 2009; 45:2249-2252.
    • (2009) Eur J Cancer , vol.45 , pp. 2249-2252
    • Ohorodnyk, P.1    Eisenhauer, E.A.2    Booth, C.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.